Galera Therapeutics Q2 EPS $(0.88) Down From $(0.75) YoY
Galera Therapeutics (NASDAQ:GRTX) reported quarterly losses of $(0.88) per share. This is a 17.33 percent decrease over losses of $(0.75) per share from the same period last year.
The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira’s CEO Placed On Temporary Leave, 5 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 17)
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 10)
Top 20 Searched Tickers In Benzinga Pro For Morning Of Friday, Apr. 30, 2021
NIO (NIO)
Amazon (AMZN)
Microvision (MVIS)
Tesla (TSLA)
Vaxart (VXRT)
Galera Therapeutics (GRTX)
ShiftPixy (PIXY)
Apple (AAPL)
Twitter (TWTR)
Ocugen (OCGN)
Motus GI (MOTS)
Facebook (FB)
SPDR S&P 500
65 Biggest Movers From Yesterday
Gainers
ShiftPixy, Inc. (NASDAQ: PIXY) jumped 33.1% to settle at $3.34 on Thursday as the company said it has been named as sponsor related to 4 SPACs.
Why Galera Therapeutics Stock is Trading Higher Today
Galera Therapeutics (NASDAQ: GRTX) shares are trading higher after the company announced updated data from its randomized, multicenter, placebo-controlled trial in patients with pancreatic cancer.